Evotec to Assist Cubist’s Antibacterial Targets for Drug Development

1 March 2010 (Last Updated March 1st, 2010 18:30)

German firm Evotec AG said it will provide its proprietary fragment-based drug discovery platform EVOlution to US company Cubist Pharmaceuticals until 2010 for its drug discovery against additional antibacterial targets. EVOlution uses biochemical and biophysical techniques including n

German firm Evotec AG said it will provide its proprietary fragment-based drug discovery platform EVOlution to US company Cubist Pharmaceuticals until 2010 for its drug discovery against additional antibacterial targets.

EVOlution uses biochemical and biophysical techniques including nuclear magnetic resonance, surface plasmon resonance and X-ray crystallography to screen low molecular weight compounds and fragments.

The platform combines orthogonal screening technologies to screen a more diverse set of biological targets than other fragment screening approaches, as well as screen the fragments in a high-throughput mode.